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Genotype-phenotype correlation studies have shown that f3 myosin heavy
chain (f3MHC) mutations are determinants of frognosis in patients with hy-
pertrophic cardiomyopathy (HCM). While Arg 19Trp mutation is associated
with a high incidence of sudden cardiac death ISCD) and an average life
expectancy of 38 years, the Val606 Met mutation is associated with a near
normal life expectancy in the families studied here. However, it is unknown
whether the prognostic significance of HCM mutations correlates with the
degree of left ventricular hypertrophy (LVH) associated with each mutation.
Accordingly, we determined the left ventricular mass index (LVMI) and the
extent of LVH in 12 patients with the Arg719Trp mutation and five patients
with the Val606Met mutation. Left ventricular mass was derived by the area-
length method using 2-D echocardiograms and indexed for body surface
area (BSA). Extent of LVH was determined using a semi-quantitative point
score method that takes into account the extent of involvement of the sep-
tum, apex, and lateral wall of the left ventricle. The mean LVMI was 147.0 ±
36 g/m2 in patients with the Arg719Trp mutation and 111.7 ± 19 g/m2 in pa-
tients with the Val606 Met mutation (p = 0.020). Similarly the extent of hyper-
trophywas greater in patients with the Arg719Trp mutation than in those with
the Val606 Met mutation 15.92 ± 2.3 vs. 3.2 ± 1.5, respectively, p = 0.015).
The mean septal thickness was also ~reater in patients with the Arg719Trp
mutation than in those with the Val60 Met mutation, however, this was not
statistically significant 12.03 ± 0.7 vs. 1.62 ± 0.26, P = 0.095). There was
no difference in the mean BSA, age, or gender among the two groups of pa-
tients. In conclusion, HCM patients, due to a malignant mutation such as the
Arg719Trp, have greater LVH than patients with a benign mutation such as
the VaI606 Met. These results indicate the grave prognosis of HCM mutations
are associated with expression of greater hypertrophy. This provides an eas-
ily detectable clinical parameter to further stratify patients at risk of sudden
death that are candidates for invasive interventions such as implantation of
cardiac defibrillators.
The Action of a Specific Natriuretic Peptide
Receptor Antagonist (HS142-1) Upon Basal
Coronary and Renal Vascular Resistances
Thanom Supaporn, Chi-Ming Wei, Lawrence L. Aahrus, Masahiko Kinoshita,
Yuzuru Matsuda, John C. Burnett Jr.. Cardiorenal Research Laboratory. Mayo Clinic
and Foundation, Rochester. Minnesota
While the natriuretic peptides, ANP (atrial), BNP (brain). and CNP (C-type),
mediate potent endothelial-independent vasorelaxing actions in vitro, the
role of the endogenous natriuretic peptide system in vascular regulation in
vivo remains unclear. HS142-1 is a novel natriuretic-peptide receptor antag-
onist derived from a fungus named Aureobasidium sp. which selectively
blocks particulate guanylate cyclase-linked natriuretic peptide A and B re-
ceptors which bind ANp, BNP and CNP and thus attenuates the generation
of cGMP To characterize the vascular actions of the endogenous natriuretic
peptide system in the control of basal coronary and renal vascular tone, six
normal male mongrel anesthetized dogs were studied while a second group
of six dogs served as control. HS142-1 was given as an intravenous bolus at
3 mglkg and five 20 minute periods were studied,
No significant change after HS142-1 was observed in MAP, HR, CO, PAP,
PCWP, renal blood flow (RBF) or renal vascular resistance (RVR) compared
to baseline. In contrast, a significant increase in coronary vascular resistance
(CVR) and decrease in coronary blood flow (CBF) was observed which was
different from the control group.
C1 (base line) C2 (20 min) C3 (40 min) C4 (60 min) C5 (80 min) C6 (210 min)
CBF 52 ± 10 41 ± 10 41 ± 9 37 ± 9' 33 ± 10' 32 ± 10'
RBF 258 ± 40 266 ± 46 251 ± 42 249 ± 40 242 ± 37 241 ± 38
CVR 2.1 ±05 3.0 ± 0.7' 2.9 ± 05' 3.5 ± 0.8' 39 ± OS' 4.0 ± 0.9'
RVR 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 01 0.4±0.1 0.4 ± 0.1 0.4 ± 0.1
CBF, RBF ~ ml/min, CVR and RVR ~ RU Data are Mean ± SE. 'denotes p < 0.05
These studies demonstrate that HS142-1 produces potent vasoconstric-
tion in the coronary but not renal vascular circulation. We therefore conclude
that the endogenous natriuretic peptide system which is of cardiac and en-
dothelial cell origin is an important regulator of basal coronary vascular tone.
Conclusions Ventricular myocytes produce ET-l mRNA but not ET-2 or ET-3
mRNAs. PEP and ET-l increase ET-l mRNA levels in myocytes. PEP-induced
hypertrophy may be mediated at least in part by ET-l generation from my-
ocytes.
Alterations in Endothelial Cell Adenosine
Receptors Mediate Endothelium-Dependent
Vasoconstriction in Experimental Vein Grafts
Mark G. Davies, Vickrum Ramkumar, Gregory J. Fulton, Per-Otto Hagen. Duke
University Medical Center. Durham, NC
Adenosine is a potent endogenous vasodilator which mediates its action
through Al and A2 receptor subtypes located on both vascular endothe-
lial and vascular smooth muscle cells (SMCI. Adenosine-mediated relax-
ation in vein grafts has not been examined. This study assesses the in
vitro isometric tension responses to specific adenosine receptor agonists
(A1: R-phenyl-isopropyl-adenosine and A2: CSG-21680; 10-9 to 10-4 M) of
common carotid external jugular vein bypass grafts (VG) in New Zealand
White rabbits. These responses were compared to those obtained in the
extemal jugular vein (JV) and in the common carotid artery (CA). All ves-
sels were precontracted with prostaglandin F2a (10--5 M). Endothelialized
and de-endothelialized vessels were examined. The Al mediated relax-
ation in JV was endothelium-independent, whereas A2 mediated relaxation
was endothelium-dependent. In CA, Al mediated relaxation was partially
endothelium-dependent, while A2 mediated relaxation was endothelium-
independent. In VG, Al activation induced endothelium-dependent vasocon-
striction. Endothelial denudation restored Al mediated relaxation, but re-
duced compared to that of JV (max. 19 ± 9%). A2 relaxation in VG was
endothelium-independent (max. 39 ± 4%). Primary cultures of arterial and
vein graft SMC expressed both A1 and A2 receptors on northern blot anal-
ysis. There was, however, a marked reduction in the A1 affinity of the SMC
from the VG compared to the arterial SMC (40.9 ± 1.3% arterial binding).
This study, therefore, demonstrates that there is a substantial change in the
adenosine mediated vasoreactivity in VG compared to JV, due to a change in
endothelial Al receptor mediated response from relaxation to constriction,
coupled with a decreased affinity of the Al receptors on the VG SMC. The
adenosine responses of the VG are also different from CA. Therefore, the
endothelial celis of VG appear to be unique, in that functionally they neither
maintain a venous phenotype nor acquire an arterial phenotype in response
to adenosine.
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Background In addition to its potent vasoactive properties, endothelin-l (El-
1) has powerful effects on cell growth and may be involved in the process
of myocardial hypertrophy. The roles of ET-2 and ET-3 in this process are
unknown. We have investigated the effects of exogenous ET-l and the a-
adrenergic agonist phenylephrine (PEP) on levels of ET-l, ET-2 and ET-3 mR-
NAs in myocytes.
Methods Neonatal rat ventricular myocytes were stimulated with ET-l or
PEP Quantitative ribonuclease protection assay and laser densitometry were
used to assay levels of the mRNAs for ET-l, ET-2 and ET-3, and constitutive
GAPDH.
Results ET-l mRNA was present in unstimulated myocytes. ET-2 and ET-
3 mRNAs were not detectable in control or stimulated myocytes. ET-l and
PEP caused a dose-dependent increase in myocyte [ET-l mRNA] relative to
[GAPDH mRNA] within 1 hour, [ET-l mRNA] remained elevated to 24 hours:
Myocyte [ET-l mRNA\. optical density units
Ventricular Myocytes in Culture Express
Endothelin-1 (ET-1) mRNA but not ET-2 mRNA or
ET-3 mRNA in Response to the Hypertrophic
Agonists Phenylephrine and ET-1
Samer Kaddoura, John Firth 1, Steven J. Fuller, Philip A. Poole-Wilson, Peter
H. Sugden. National Heart and Lung Institute, London; 1Institute ofMolecular
Medicine, Oxford, England
means ± sem, n = 3, 'p < 0.05, t p < 0.005 relative to control
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